Novel antibacterial nanofibrous PLLA scaffolds

Journal of Controlled Release

Volumn 146, Issue 3, 2010, Pages 363-369

  Feng, Kai ^a   Sun, Hongli ^a   Bradley, Mark A ^a   Dupler, Ellen J ^a   Giannobile, William V ^a,b   Ma, Peter X ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

^b UNIVERSITY OF MICHIGAN SCHOOL OF DENTISTRY   (United States)

Author keywords

Controlled delivery; Doxycycline; Nanofiber; Scaffold; Tissue engineering

Indexed keywords

ANTIBACTERIAL TESTS; BACTERIAL GROWTH; BONE INFECTION; BURST RELEASE; CONTROLLED DELIVERY; CONTROLLED RELEASE; DOXYCYCLINE; E. COLI; EMULSION METHOD; FIBROUS SCAFFOLDS; GROWTH FACTOR; HYDROPHILIC DRUGS; IN-VITRO; PHYSICAL AND CHEMICAL PROPERTIES; PLGA NANO-SPHERES; PLLA; POROUS STRUCTURES; POROUS TISSUE; RELEASE KINETICS; S. AUREUS; SIDE EFFECT; WATER-IN-OIL;

ANTIBIOTICS; BACTERIOLOGY; BIOACTIVITY; CHEMICAL PROPERTIES; DRUG INTERACTIONS; EMULSIFICATION; ESCHERICHIA COLI; NANOFIBERS; NANOSPHERES; THREE DIMENSIONAL; TISSUE; TISSUE ENGINEERING;

SCAFFOLDS;

DOXYCYCLINE; LAKESHORE BIOMATERIALS; NANOFIBER; NANOSPHERE; POLYGLACTIN; POLYLACTIC ACID; TISSUE SCAFFOLD; UNCLASSIFIED DRUG; WATER OIL CREAM;

ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIAL GROWTH; CONTROLLED DRUG RELEASE; DRUG DELIVERY SYSTEM; ESCHERICHIA COLI; NANOPHARMACEUTICS; NONHUMAN; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS; TISSUE ENGINEERING;

ANTI-BACTERIAL AGENTS; DELAYED-ACTION PREPARATIONS; DOXYCYCLINE; ESCHERICHIA COLI; LACTIC ACID; NANOFIBERS; POLYGLYCOLIC ACID; POLYMERS; POROSITY; STAPHYLOCOCCUS AUREUS; TISSUE SCAFFOLDS;

EID: 77956341686     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jconrel.2010.05.035     Document Type: Article

References (44)

1. JM A. Epidemiology and risk factors of periodontal diseases. Dent. Clin. North Am. 2005, (49):517-532.
2. Bokor-Bratic M., Brkanic T. Clinical use of tetracyclines in the treatment of periodontal diseases. Med. Pregl. 2000, 53(5-6):266-271.
3. V.L., Stratton C.W. Mechanisms of action for antimicrobial agents: general principals and mechanisms for selected classes of antibiotics. Antibiotics in Laboratory Medicine 1996, Williams & Wilkins, Baltimore. 4th ed.
4. Seymour R.A., Heasman P.A. Tetracyclines in the management of periodontal diseases. A review. J. Clin. Periodontol. 1995, 22(1):22-35.
5. Amin A.R., Attur M.G., Thakker G.D., Patel P.D., Vyas P.R., Patel R.N., Patel I.R., Abramson S.B. A Novel Mechanism of Action of Tetracyclines: Effects on Nitric Oxide Synthases. Proc. Natl. Acad. Sci. U. S. A. 1996, 93(24):14,014-14,019.
6. Gapski R., Hasturk H., Van Dyke Thomas E., Oringer Richard J., Wang S., Braun Thomas M., Giannobile William V. Systemic MMP inhibition for periodontal wound repair: results of a multi-centre randomized-controlled clinical trial. J. Periodontol. 2009, 36(2):149-156.
7. Giannobile W.V. Host-response therapeutics for periodontal diseases. J. Periodontol. 2008, 79(8, Suppl):1592-1600.
8. Greenwald R.A., Moak S.A., Ramamurthy N.S., Golub L.M. Tetracyclines suppress matrix metalloproteinase activity in adjuvant arthritis and in combination with flurbiprofen, ameliorate bone damage. J. Rheumatol. 1992, 19(6):927-938.
9. Shlopov B.V., Stuart J.M., Gumanovskaya M.L., Hasty K.A. Regulation of cartilage collagenase by doxycycline. J. Rheumatol. 2001, 28(4):835-842.
10. Joshi N., Miller D.Q. Doxycycline revisited. Arch. Intern. Med. 1997, 157(13):1421-1428.
11. Slots J., Rams T.E. Antibiotics in periodontal therapy: advantages and disadvantages. J. Periodontol. 1990, 17(7 ( Pt 2)):479-493.
12. Klein N.C., Cunha B.A. Tetracyclines. Med. Clin. North Am. 1995, 79(4):789-801.
13. Seymour R.A., Heasman P.A. Tetracyclines in the management of periodontal-diseases - a review. J. Periodontol. 1995, 22(1):22-35.
14. Attar S.M. Tetracyclines: what a rheumatologist needs to know?. International Journal of Rheumatic Diseases 2009, 12(2):84-89.
15. Loesche W.J. The antimicrobial treatment of periodontal disease: changing the treatment paradigm. Critical Reviews in Oral Biology & Medicine 1999, 10(3):245-275.
16. Mombelli A., Samaranayake L.P. Topical and systemic antibiotics in the management of periodontal diseases. Int. Dent. J. 2004, 54(1):3-14.
17. McIlwraith C.W. Treatment of infectious arthritis. Veterinary Clinics of North America-Large Animal Practice 1983, vol. 5,(2):363-379.
18. van der Ouderaa F.J. Anti-plaque agents. Rationale and prospects for prevention of gingivitis and periodontal disease. J. Periodontol. 1991, 18(6):447-454.
19. Esposito E., Cortesi R., Cervellati F., Menegatti E., Nastruzzi C. Biodegradable microparticles for sustained delivery of tetracycline to the periodontal pocket: formulatory and drug release studies. J. Microencapsul. 1997, 14(2):175-187.
20. Goodson J.M., Holborow D., Dunn R.L., Hogan P., Dunham S. Monolithic tetracycline-containing fibers for controlled delivery to periodontal pockets. J. Periodontol. 1983, 54(10):575-579.
21. Haerdi-Landerer M.C., Suter M.M., Steiner A., Wittenbrink M.M., Pickl A., Gander B.A. In vitro cell compatibility and antibacterial activity of microencapsulated doxycycline designed for improved localized therapy of septic arthritis. J. Antimicrob. Chemother. 2008, 61(2):332-340.
22. Kenawy E.-R., Bowlin G.L., Mansfield K., Layman J., Simpson D.G., Sanders E.H., Wnek G.E. Release of tetracycline hydrochloride from electrospun poly(ethylene-co-vinylacetate), poly(lactic acid), and a blend. J. Control Release. 2002, 81(1-2):57-64.
23. Mundargi R.C., Srirangarajan S., Agnihotri S.A., Patil S.A., Ravindra S., Setty S.B., Aminabhavi T.M. Development and evaluation of novel biodegradable microspheres based on poly(d,l-lactide-co-glycolide) and poly(e-caprolactone) for controlled delivery of doxycycline in the treatment of human periodontal pocket: in vitro and in vivo studies. J. Control Release. 2007, 119(1):59-68.
24. Schwach-Abdellaoui K., Vivien-Castioni N., Gurny R. Local delivery of antimicrobial agents for the treatment of periodontal diseases. Eur. J. Pharm. Biopharm. 2000, 50(1):83-99.
25. Tamimi F., Torres J., Bettini R., Ruggera F., Rueda C., Lopez-Ponce M., Lopez-Cabarcos E. Doxycycline sustained release from brushite cements for the treatment of periodontal diseases. J. Biomed. Mater. Res. A. 2008, 85A(3):707-714.
26. Mundargi R.C., Babu V.R., Rangaswamy V., Patel P., Aminabhavi T.M. Nano/micro technologies for delivering macromolecular therapeutics using poly(d,l-lactide-co-glycolide) and its derivatives. J. Control. Release. 2008, 125(3):193-209.
27. Wang X.Q., Wenk E., Zhang X.H., Meinel L., Vunjak-Novakovic G., Kaplan D.L. Growth factor gradients via microsphere delivery in biopolymer scaffolds for osteochondral tissue engineering. J. Control. Release. 2009, 134(2):81-90.
28. Kakizawa Y., Nishio R., Hirano T., Koshi Y., Nukiwa M., Koiwa M., Michizoe J., Ida N. Controlled release of protein drugs from newly developed amphiphilic polymer-based microparticles composed of nanopcarticles. J. Control. Release. 2010, 142(1):8-13.
29. Bae S.E., Son J.S., Park K., Han D.K. Fabrication of covered porous PLGA microspheres using hydrogen peroxide for controlled drug delivery and regenerative medicine. J. Control. Release. 2009, 133(1):37-43.
30. Kim H.K., Chung H.J., Park T.G. Biodegradable polymeric microspheres with "open/closed" pores for sustained release of human growth hormone. J. Control. Release. 2006, 112(2):167-174.
31. Goraltchouk A., Scanga V., Morshead C.M., Shoichet M.S. Incorporation of protein-eluting microspheres into biodegradable nerve guidance channels for controlled release. J. Control. Release. 2006, 110(2):400-407.
32. Wei G., Jin Q., Giannobile W.V., Ma P.X. Nano-fibrous scaffold for controlled delivery of recombinant human PDGF-BB. J. Control. Release. 2006, 112(1):103-110.
33. Wei G., Jin Q., Giannobile W.V., Ma P.X. The enhancement of osteogenesis by nano-fibrous scaffolds incorporating rhBMP-7 nanospheres. Biomaterials 2007, 28(12):2087-2096.
34. Wei G., Ma P.X. Macroporous and nanofibrous polymer scaffolds and polymer/bone-like apatite composite scaffolds generated by sugar spheres. J. Biomed. Mater. Res. A. 2006, 78A(2):306-315.
35. Woo K.M., Chen V.J., Ma P.X. Nano-fibrous scaffolding architecture selectively enhances protein adsorption contributing to cell attachment. J. Biomed. Mater. Res. A. 2003, 67A(2):531-537.
36. Woo K.M., Jun J.-H., Chen V.J., Seo J., Baek J.-H., Ryoo H.-M., Kim G.-S., Somerman M.J., Ma P.X. Nano-fibrous scaffolding promotes osteoblast differentiation and biomineralization. Biomaterials 2006, 28(2):335-343.
37. Li Y., Jiang H.L., Zhu K.J., Liu J.H., Hao Y.L. Preparation, characterization and nasal delivery of alpha-cobrotoxin-loaded poly(lactide-co-glycolide)/polyanhydride microspheres. J. Control. Release. 2005, 108(1):10-20.
38. Schwendeman S.P., Tobio M., Joworowicz M., Alonso M.J., Langer R. New strategies for the microencapsulation of tetanus vaccine. J. Microencapsul. 1998, 15(3):299-318.
39. Kim K., Luu Y.K., Chang C., Fang D., Hsiao B.S., Chu B., Hadjiargyrou M. Incorporation and controlled release of a hydrophilic antibiotic using poly(lactide-co-glycolide)-based electrospun nanofibrous scaffolds. J. Control. Release. 2004, 98(1):47-56.
40. Wei G.B., Pettway G.J., McCauley L.K., Ma P.X. The release profiles and bioactivity of parathyroid hormone from poly(lactic-co-glycolic acid) microspheres. Biomaterials 2004, 25(2):345-352.
41. Kawashima Y., Yamamoto H., Takeuchi H., Hino T., Niwa T. Properties of a peptide containing Dl-lactide/glycolide copolymer nanospheres prepared by novel emulsion solvent diffusion methods. Eur. J. Pharm. Biopharm. 1998, 45(1):41-48.
42. Yin J., Noda Y., Yotsuyanagi T. Properties of poly(lactic-co-glycolic acid) nanospheres containing protease inhibitors: camostat mesilate and nafamostat mesilate. Int. J. Pharm. 2006, 314(1):46-55.
43. Stoller N.H., Johnson L.R., Trapnell S., Harrold C.Q., Garrett S. The pharmacokinetic profile of a biodegradable controlled-release delivery system containing doxycycline compared to systemically delivered doxycycline in gingival crevicular fluid, saliva, and serum. J. Periodontol. 1998, 69(10):1085-1091.
44. Smith G.N., Mickler E.A., Hasty K.A., Brandt K.D. Specificity of inhibition of matrix metalloproteinase activity by doxycycline. relationship to structure of the enzyme. Arthritis Rheum. 1999, 42(6):1140-1146.